Future research should aim to assess the efficacy of combination treatments utilizing IGF1R inhibition and IRA inhibition, lowering insulin and the use of personalized treatments based on tumor biomarkers and ligand levels in patients with solid tumors and, in particular, in patients with Ewing sarcoma. This evidence concerns the gene IGF1R and Ewing sarcoma.